Tag: Diabetes: Type II
Long-Term Pioglitazone Safe, Effective for NASH, T2DM
Safe and effective for patients with prediabetes or type 2 diabetes and nonalcoholic steatohepatitis
Dulaglutide, Glargine Plus Lispro Improve Glycemic Control
Dulaglutide and glargine plus lispro result in similar proportion of glucose values in normoglycemic range
Vildagliptin, Sitagliptin Have Similar Effects on Incretin
Inter-individual variability seen in L-cell feedback induced by DPP-4 inhibitors
Varying Safety of Add-On Second-Line T2DM Treatments
For patients taking metformin, TZD and DPP-4i linked to lower mortality, cardiovascular risks
Genetic Data Help ID Risk of Future Impaired Fasting Glucose
Genetic score, clinical risk factors can ID children at high risk for impaired fasting glucose, T2DM
Even Short-Term T2DM Remission Reduces Risk of Microvascular Dz
Length of time spent in remission inversely related to risk of microvascular disease
ADA: Empagliflozin Linked to Reduction in T2DM Nephropathy
Reduction in incident or worsening nephropathy, and in doubling of serum creatinine level
CYP2C8, SLCO1B1 Variants Impact Response to Rosiglitazone
Genetic variants have clinical impact on response to rosiglitazone, but not pioglitazone
Postural Instability Predicts Off-Loading Nonadherence in T2DM
Better off-loading predicted by larger and more severe DFUs, more severe neuropathy, foot pain
No Significant Weight Change With Adjuvant Sulfonylureas
Addition maintains glycemic control without weight change among patients with T2DM taking metformin
